scholarly journals Central retinal thickness following panretinal photocoagulation using a multispot semi‐automated pattern‐scanning laser to treat ischaemic diabetic retinopathy: Treatment in one session compared with four monthly sessions

2018 ◽  
Vol 97 (5) ◽  
Author(s):  
Pierre‐Henry Gabrielle ◽  
Pascale Massin ◽  
Laurent Kodjikian ◽  
Ali Erginay ◽  
Charlotte Pallot ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Retinal Thickness ◽  
Central Retinal Thickness ◽  
Scanning Laser ◽  
Panretinal Photocoagulation

Decreased OCT measured central retinal thickness in patients with and without minimal diabetic retinopathy

2007 ◽  
Vol 85 ◽  
pp. 0-0
Author(s):  
PHB KOK ◽  
HW VAN DIJK ◽  
C BIALLOSTERSKI ◽  
MEJ VAN VELTHOVEN ◽  
FD VERBRAAK
Keyword(s):  
Diabetic Retinopathy ◽  
Retinal Thickness ◽  
Central Retinal Thickness

scholarly journals Anatomical and visual outcome of intravitreal bevacizumab (Avastin) in patients with diabetic macular edema

2016 ◽  
Vol 8 (1) ◽  
pp. 54-61
Author(s):  
Shyam Vyas ◽  
Raba Thapa ◽  
Sanyam Bajimaya ◽  
Eli Pradhan ◽  
Govinda Paudyal
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Retinal Thickness ◽  
Intravitreal Bevacizumab ◽  
Visual Outcome ◽  
Central Retinal Thickness ◽  
Post Injection ◽  
Macular Volume

Background: Intravitreal bevacizumab has been shown to be an effective treatment of diabetic macular edema. Objective: To assess the anatomical and visual outcome of intravitrealbevacizumab (Avastin) in patients of diabetic macular edema. Materials and methods: 52 eyes of 33 patients with diabetic retinopathy with CSME were included in this study. Detailed ophthalmic examination, including best-corrected visual acuity(BCVA), stereoscopic biomicroscopy, and retinal thickness measurement by Optical coherence tomography (OCT), was done at baseline and at each follow- up visit. All patients were treated with 0.05 mL intravitreal injection containing 1.25 mg of bevacizumab and repeat injection was given in cases of recurrent/persistent subretinal or intraretinal fluid shown by OCT and deterioration of BCVA. Results: All patients completed 6 months of follow-up with mean number of 2.78 intravitreal injections per eye.The mean BCVA at baseline was 0.80 log MAR, with significant changes 0.68 (p=0.012), 0.63 (p=<0.001) and 0.60 log MAR (p=<0.001) at 6 weeks, 3 months, and 6 months respectively. Final BCVA analysis demonstrated that 25 eyes (48.07%) remained stable and 22 (42.30%) improved ≥2 lines on BCVA. The mean central retinal thickness was 449.03 μm at baseline and it decreased significantly to 410.09 (p<0.001),345.76(p<0.001), 344.55(p<0.001) and 326.51(p<0.001) at 1st day, 6 weeks, 3 months and 6 months post injection, respectively. Mean macular volume changed significantly from baseline of 10.77 μm to 10.33μm (p<0.001) 8.97 (p<0.001), 8.82 (p<0.001), 8.95 (p<0.001) at 1st day, 6 weeks, 3 months and 6 months post injection respectively. Conclusion: Intravitreal bevacizumab injection resulted in significant improvement in BCVA, central retinal thickness and total macular volume in patients with diabetic retinopathy with CSME, and this beneficial effect is maximum at 6 weeks. Also, slight reduction in these parameters at 3 month follow up suggests that visual improvement and stable macular thickness can be maintained longer with injection frequency of probably 6-12 weeks. Nepal J Ophthalmol 2016; 8(15): 54-61

scholarly journals A study of therapeutic effects of 670 nm irradiation in different types of diabetic macular edema

2021 ◽  
Vol 9 (4) ◽  
pp. 15-22
Author(s):  
S. Ramin ◽  
M. Ahadi ◽  
A. Ebrahimi
Keyword(s):  
Visual Acuity ◽  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Retinal Thickness ◽  
Central Retinal Thickness ◽  
Diabetic Patients ◽  
Therapeutic Effects ◽  
Positive Effects ◽  
The Mean

The purpose of this study was to investigate the therapeutic effects of 670 nm irradiation in patients with diabetic macular edema. In several studies, positive effects of red/near-infrared irradiation showed in a range of ocular diseases such as macular degeneration, macular edema, and retinitis pigmentosa. This study was conducted on forty five eyes of 26 diabetic patients with macular edema between the ages of 51 and 80.Measurement of visual acuity and slit lamp examination, funduscopy, and optical coherence tomography were performed in all subjects. None of the patients had proliferative retinopathy. We used a portable LED device (Warp 10, Quantum Devices) for treatment. Patients held this device at a distance of 3 cm from their eyes for 240 seconds for three months. Full ophthalmic examinations were repeated 1, 2, and 3 months after treatment.After 3 months, the mean visual acuity improved from 0.44 ± 0.38 log MAR to 0.27 ± 0.24 log MAR and vision increased by 1.52 ± 1.16 lines post treatment (р<0.001). The mean central macula thickness decreased from 381.49 ± 144.40 μm to 359.72 ± 128.84 μm (р=0.050). In patients with mild and moderate nonproliferative diabetic retinopathy, the mean central retinal thickness decreased 52.06 ± 67.78 μm and 39.27 ± 44.69 μm, respectively, but patients with severe type showed an increase of 34.93 ± 65.65 μm in the mean central retinal thickness (р<0.001). Also, the severity of macular edema had no effect on final outcomes (р>0.05). Photobiomodulation can positively affect diabetic macular edema, especially in patients with mild to moderate diabetic retinopathy.

scholarly journals Efficacy and Safety of Various Treatments for Proliferative Diabetic Retinopathy: A Systematic Review and Network Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Bo Zhang ◽  
Zhulin Zhou ◽  
Bingjie Zhang ◽  
Dan Wang
Keyword(s):  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Adverse Reactions ◽  
Retinal Thickness ◽  
Meta Analysis ◽  
Central Retinal Thickness ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Severe Stage ◽  
Total Blindness

Diabetic retinopathy is the main cause of visual impairment and blindness. The proliferative diabetic retinopathy at the severe stage of diabetic retinopathy is more harmful to vision and even leads to total blindness. To evaluate the visual acuity, central retinal thickness, and adverse reactions of various treatments for proliferative diabetic retinopathy through a systematic network meta-analysis. The relevant research published in English or Chinese from January 1, 2011, to February 1, 2021, was systematically searched by using PubMed, science network, EMBASE, MEDLINE, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and other electronic databases. A total of 15 studies were selected, including 3,222 eyes of PDR patients. Our results show that in terms of visual score improvement, ranibizumab alone (69.90%) and laser + ranibizumab (67.90%) are the best. However, if the groups were grouped again according to the dose and times of ranibizumab injection, the results showed that 0.5 mg ranibizumab injection per month (58.0%) had the best effect on vision improvement. For the change of central retinal thickness, the thickness decreased the most after the laser combined with ranibizumab (96.5%). After the same subgroup analysis, the results were further refined into the best effect of laser combined with 0.3 mg ranibizumab per quarter (72.7%). In addition, our analysis of complications also showed that the overall incidence of adverse reactions of PRP (11.1 ± 12.4, %) was greater than that of ranibizumab (10.6 ± 13.0, %). However, more high-quality randomized controlled trials with longer follow-up using standard methods are still needed to verify the correlation.

scholarly journals Effect of pattern scanning laser on macular thickness in diabetic retinopathy

2021 ◽  
Vol 13 ◽  
pp. 251584142110358
Author(s):  
Nadine Hamed ◽  
Logan Vander Woude ◽  
Ramak Roohipourmoallai ◽  
Collin Ohning ◽  
Kathleen A. Regan ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Treatment Group ◽  
Macular Edema ◽  
Macular Thickness ◽  
Scanning Laser ◽  
Treatment Modalities ◽  
Panretinal Photocoagulation ◽  
Anti Vegf ◽  
Spot Number ◽  
Time Point

Purpose: This study investigates the effect of pattern scanning laser (PASCAL) panretinal photocoagulation (PRP) on central macular thickness (CMT) and visual acuity (VA) in patients with proliferative diabetic retinopathy (PDR). Methods: This retrospective non-randomized comparative case series included 262 eyes (163 with macular edema) of 177 patients with PDR. Treatment was PRP alone (137), PRP + anti-vascular endothelial growth factor (VEGF) (69), PRP + focal laser (28), or all three (89). CMT and central macular volume 3 and 6 mm from fovea were analyzed before and 1, 3, and 6 months after PRP. Spot number was plotted against CMT, and linear regression analysis was performed. Results: For each treatment group and time point, there was a non-significant relationship between spot number and CMT. In eyes receiving all three treatment modalities, a significant negative relationship was found between spot number and 3-mm volume at 6 months ( p = 0.04) and 6-mm volume at 1 month ( p = 0.002) and 6 months ( p = 0.011). There was no significant change in VA in any treatment group at the 6-month time point. Conclusion: PASCAL PRP ± focal laser or anti-VEGF was not associated with increased development of macular edema or change in VA. PASCAL PRP with focal laser and anti-VEGF may result in a decrease in macular edema.

Sign in / Sign up

Export Citation Format

Share Document